With genetic engineering, systems explored in this book now exist allowing for the simple, efficient, and near universally precise genetic manipulation directly in any organism, including the mouse. Herein, these models are applied to a wide field of disease areas, including diabetes, cardiovascular disease, skin disorders, cancer, neurodegenerative and neuromuscular diseases, retinal disorders, as well as various behavioral models. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Practical and fully updated, Mouse Models for Drug Discovery: Methods and Protocols, Second Edition serves to equip the reader with an extensive overview of techniques to utilize the many possibilities of mice in the drug development process.

This book would combine chapters written by the most qualified authors around the world whose research encompasses the effect of morphine or other opioids on tumor growth and metastasis. This includes clinicians involved in trials determining which type of post surgical pain management can minimize the risk of recurrence or metastasis, researchers working on animal models and studying the effect of morphine on tumors, and most importantly the mechanism for this effect, and lastly cell biologists. There is currently a lot of research going on trying to reconcile the pro- and anti-cancer aspects of opioids actions.

This volume addresses one of the Holy Grails in Psychiatry, namely the evidence for and potential to adopt 'Biomarkers' for prevention, diagnosis, and treatment responses in mental health conditions. It meshes together state of the art research from international renowned pre-clinical and clinical scientists to illustrate how the fields of anxiety disorders, depression, psychotic disorders, and autism spectrum disorder have advanced in recent years.

This second edition is a one-source guide to current information about red blood cell physiology and the action of native and recombinant human erythropoietic factors. Topics in the fields of erythropoiesis, recombinant protein discovery and production, and treatment of patients with anemia due to renal failure, cancer, or chronic diseases are covered. The newest theories in erythropoiesis (receptors, signaling), manufacturing, new formulations, and clinical research are discussed.

This book is of interest to researchers and clinical investigators in academia and biotechnology and pharmaceutical companies, to clinical research associates, clinical monitors, and physician investigators.

Non-clinical drug safety evaluation, the assessment of the safety profile of therapeutic agents through the conduct of laboratory studies in in vitro systems and in animals, is an essential step in the progress of new pharmaceuticals heading toward the ultimate goal of clinical trials and, eventually, approval. In Drug Safety Evaluation: Methods and Protocols, expert researchers detail a compendium of analytical technologies with a focus on clarity and applicability in real life laboratory practice. These meticulous contributions feature key topics such as acute to chronic general toxicity studies, histopathology studies, reproductive toxicity studies, genotoxicity studies, safety pharmacology studies, investigative toxicity studies, and safety biomarker studies. As a volume in the highly successful Methods in Molecular Biology(TM) series, chapters include brief introductions to their respective subjects, lists of the necessary materials, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Drug Safety Evaluation: Methods and Protocols serves as an ideal guide to this field, helpful to pharmaceutical scientists, toxicologists, biochemists, and molecular biologists as well as scientists from all other disciplines who wish to translate these thorough methods into their own work.

Provides an understanding of (mostly) enzymatic reactions that are responsible for the function and maintenance of living things This innovative text for non-biochemistry majors includes introductory material at the beginning of each chapter that contextualizes chapter themes in real-life scenarios Online supporting materials with further opportunities for research and investigation Synthesis questions at the end of each chapter that encourage students to make connections between concepts and ideas, as well as develop critical-thinking skills

This volume provides a broad overview of important new advances in the field of Neuropharmacology. In 20 chapters, a selection of international contributors discuss topics including endocannabinoid function, pain, stress, astrocytes etc, and new possibilities for treatments of neurological diseases with neuropharmacological approaches.
- Cutting-edge articles in neuropharmacology
- Discusses new possibilities for treatments of neurological disorders
- Very international authorship providing a global view of the state of research

Contents

Philip C. Sharpe, Rosemary S. Harrison, and David P. Fairlie: Amyloid Peptides and Proteins in Review. - Marilena Kampa, Artemissia-Phoebe Nifli, George Notas, Elias Castanas: Polyphenols and Cancer Cell Growth. - Michal Janitz: Assigning Functions to Genes The Main Challenge of the Post-Genomic Era. - Brigittte M. Jockusch, Kai Murk and Martin Rothkegel: The Profile of Profilins.

"Neurological Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer s disease, Parkinson s disease, Huntington disease, ALS, and the epilepsies. "Neurological Disorders "has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the second volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" 978-0-12-373861-5, which is also available for purchase individually.
- Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process
- Critical evaluation of animal and translational models improving transition from drug discovery and clinical development
- Emphasis on what results mean to the overall drug discovery process
- Exploration of issues in clinical trial design and conductance in each therapeutic area"

"Psychiatric Disorders" is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. "Psychiatric Disorders "has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on "Animal and Translational Models for CNS Drug Discovery" is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery.

This is the first volume in the three volume-set, "Animal and Translational Models for CNS Drug Discovery" 978-0-12-373861-5, andis also available for purchase individually.
Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery processCritical evaluation of animal and translational models improving transition from drug discovery and clinical developmentEmphasizes what results mean to the overall drug discovery processExplores issues in clinical trial design and conductance in each therapeutic areaPsychiatric Disorders is available for purchase individually."

Traditional medicinal knowledge, especially the use of ethnomedicinal plants in developing countries, has been passed down for generations. Today, however, scientists are poised to combine traditional medicinal plants and modern drug discoveries to further develop essential products that have followed the leads of indigenous cures used for centuries. Ethnomedicinal Plant Use and Practice in Traditional Medicine provides emerging research exploring the theoretical and practical aspects of indigenous knowledge and therapeutic potential within ethnobotany. Featuring coverage on a broad range of topics such as drug discovery, traditional knowledge, and herbal medicine, this book is ideally designed for doctors, healers, medical professionals, ethnobotanists, naturalists, academicians, researchers, and students interested in current research on the medical use and applications of natural-based resources.

Volumes in this widely revered series present comprehensive reviews of drug substances and additional materials, with critical review chapters that summarize information related to the characterization of drug substances and excipients. This organizational structure meets the needs of the pharmaceutical community and allows for the development of a timely vehicle for publishing review materials on this topic.
The scope of the Profiles series encompasses review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodology related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients.
* Presents comprehensive reviews covering all aspects of drug development and formulation of drugs
* Profiles creatine monohydrate and fexofenadine hydrochloride, as well as five others
* Meets the information needs of the drug development community

With more restrictions upon animal experimentations, pharmaceutical industries are currently focusing on a new generation of experiments and technologies that are considerably more efficient and less controversial. The integration of computational and experimental strategies has led to the identification and development of promising compounds. Computer Applications in Drug Discovery and Development is a pivotal reference source that provides innovative research on the application of computers for discovering and designing new drugs in modern molecular biology and medicinal chemistry. While highlighting topics such as chemical structure databases and dataset utilization, this publication delves into the current panorama of drug discovery, where high drug failure rates are a major concern and properly designed virtual screening strategies can be a time-saving, cost-effective, and productive alternative. This book is ideally designed for chemical engineers, pharmacists, molecular biologists, students, researchers, and academicians seeking current research on the unexplored avenues and future perspectives of drug design.

Product information not available.

Living systems exhibit a fundamental contradiction: they are highly stable and reliable, yet they have the capacity to adapt to changing environmental conditions. This paradoxical behavior arises from the complexity of life--a high degree of order and cooperation that emerges from relatively simple interactions among cellular components. The Complexity Paradox proposes inventive, interdisciplinary approaches to maintaining health and managing and preventing disease by considering the totality of human biology, from the cellular level on up to entire populations of individuals. From the perspective of complexity, which acknowledges that there are limits to what we can know, Kenneth L. Mossman opens the door to understanding essential life processes in new and extraordinary ways. By tying together evolution, functional dynamics, and investigations into how the body processes energy and uses genetic information, Mossman's analysis expresses a unified theory of biology that fills a critical niche for future research in biology, medicine, and public health.

Computational methods, and in particular quantum chemistry, have taken the lead in our growing understanding of noncovalent forces, as well as in their categorization. This volume describes the current state of the art in terms of what we now know, and the current questions requiring answers in the future. Topics range from very strong (ionic) to very weak (CH-- ) interactions. In the intermediate regime, forces to be considered are H-bonds, particularly CH--O and OH--metal, halogen, chalcogen, pnicogen and tetrel bonds, aromatic stacking, dihydrogen bonds, and those involving radicals. Applications include drug development and predictions of crystal structure.

Theintentionofthisbookistoprovideacomprehensiveandcontemporaryreview ofthebiologyofsensorynerves. InkeepingwiththethemeoftheHandbookof Experimental Pharmacology series, emphasis will be placed on the actions of drugs,transmittersandautacoidsthatinitiateorinhibitsensorynerveactivation (through actionsonionchannelsandreceptorsattheirperipheralterminals)or modulate the release or actions of the transmitters released from the central terminalsofsensorynerves. Onthebasisofextensivesupportiveevidenceinthe literature, it is our view that many diseases are characterized by alterations in sensorynervefunction(e. g. pain,cardiovasculardiseaseandmigraine). Itisour beliefthatthisbookwillbeunique,asitwillcomprehensivelycovertheroleof sensory nerves across many therapeutic areas. To address directly one of the editorialboardqueries,thisisnotintendedtobeabookaboutthepharmacology ofpain. Thatsaid,tomostpharmacologists,painisthemostobviousindicationfor aroleorsensorynervesindisease. Webelievethatthelessonslearntfromthestudy ofneuropathicpainwillbeinvaluableforresearchersintheothertherapeuticareas covered inthisvolume. Sincemostinterest hasfocusedontheroleofsensory nervesinneuropathicpain,wehaveaddedanumberofchaptersdevotedtothis subject. Thebookisorganizedinthreeparts,coveringthetypesandrolesofsensory nervesinsomaticandvisceraldisorders(PartI),speci?ctargetsonsensorynerves relevanttopainandvisceraldisorders(PartII)andadescriptionofcurrentand futuretherapeuticstrategiesfortargetingsensorynerves(PartIII). The?rsttwochaptersinPartIaredevotedtodescribingtheclinicalfeaturesof neuropathicpainandvisceralpain. Ourintentionisfortheauthorstoprovidea clinicalviewpointonthefeaturesoftheseconditionsandtheadvantages/disadv- tagesofcurrenttreatmentmodalities. Thenext?vechaptersinPartIfocusonthe roleofsensorynervesinotherpathologicalconditions. Severalcommonthemes willemergeinthispart,includingthemodeofsensorynerveactivationinvarious tissues and organs, the alterations in sensory nerve excitability associated with disease,andtheimportanceofin?ammationandin?ammatorymediatorsininiti- ingalteredsensorynervefunctionindisease. v vi Preface Whilstthe?rstpartfocusesontheclinicaland/orsystemsphysiology,PartIIhas itsfocusatthecellandmolecularlevel. Thisparthighlightsthecurrentundersta- ingofproteins/ionchannels/mediatorsthathavecreatedthemostintenserecent interestintheareaofsensorynervebiology. Together,thesechapterswillgivethe reader important knowledge about how sensory nerve function can be altered pharmacologically. Thelastchapterinthispartdescribestheprocessesthatgive risetoalteredneuralre?exesatthecentrallevel. Themechanismsdescribedin thesechaptersreinforcetheroleofproteins/mediatorshighlightedinthepreceding chapters. Theroleofthesecellular,molecularandphysiologicalprocessesinthe diseasesdiscussedinPart1areemphasized. TheaimofPartIIIistohighlightpotentialdrugtargetsthatmightaltersensory nervefunction. Mostoftheworkhasbeendevotedtothetreatmentofneuropathic painandsothispartheavilyemphasizesthissubject. However,aswillbeapparent fromPartI,manyofthesetargetscouldbeutilizedinothertherapeuticareasthat implicatesensorynervesintheirpathophysiologicalprocesses. Thefocusofthe chaptersisonopioidsandmodulatorsofionchannelsandthenthe?nalchapteris devotedtofuturetreatmentstrategiesforneuropathicpain. Finally,wewouldliketothankallthecontributors,includingco-authors,who agreedtowritechaptersforthisbookandthepublishers,especiallySusanneDathe, fortheirpatienceandassistance. Baltimore B. J. Canning London D. Spina Contents PartI RoleofSensoryNervesinDisease NeuropathicPain:AClinicalPerspective ...3 RalfBaron VisceralPain:TheNeurophysiologicalMechanism...31 JyotiN. Sengupta Migraine ...75 SilviaBenemei,PaolaNicoletti,JayG. Capone,Francesco DeCesaris,andPierangeloGeppetti AfferentNerveRegulationofBladderFunctioninHealth andDisease ...91 WilliamC. deGroatandNaokiYoshimura SensoryNervesandAirwayIrritability...139 B. J. CanningandD. Spina RegulationofCardiacAfferentExcitabilityinIschemia...185 Liang-WuFuandJohnC. Longhurst RolesofGastro-oesophagealAfferentsintheMechanisms andSymptomsofRe?uxDisease ...227 AmandaJ. PageandL. AshleyBlackshaw PartII CellandMolecularMechanismsRegulatingSensory NerveFunction TransientReceptorPotentialChannelsonSensoryNerves ...261 S. R. EidandD. N. Cortright Acid-SensitiveIonChannelsandReceptors ...283 PeterHolzer PurinesandSensoryNerves...333 GeoffreyBurnstock vii viii Contents Sensory-Nerve-DerivedNeuropeptides: PossibleTherapeuticTargets ...393 ElizabethS. Fernandes,SabineM. SchmidhuberandSusanD. Brain CytokineandChemokineRegulationofSensory NeuronFunction ...417 RichardJ. Miller,HosungJung,SoniaK. BhangooandFletcherA. White TheRoleofPeptidesinCentralSensitization ...451 V. S. Seybold PartIII CurrentandFutureTreatmentStrategiesTargeting SensoryNerves OpioidsandSensoryNerves ...495 ChristophSteinandChristianZoTheintentionofthisbookistoprovideacomprehensiveandcontemporaryreview ofthebiologyofsensorynerves. InkeepingwiththethemeoftheHandbookof Experimental Pharmacology series, emphasis will be placed on the actions of drugs,transmittersandautacoidsthatinitiateorinhibitsensorynerveactivation (through actionsonionchannelsandreceptorsattheirperipheralterminals)or modulate the release or actions of the transmitters released from the central terminalsofsensorynerves. Onthebasisofextensivesupportiveevidenceinthe literature, it is our view that many diseases are characterized by alterations in sensorynervefunction(e. g. pain,cardiovasculardiseaseandmigraine). Itisour beliefthatthisbookwillbeunique,asitwillcomprehensivelycovertheroleof sensory nerves across many therapeutic areas. To address directly one of the editorialboardqueries,thisisnotintendedtobeabookaboutthepharmacology ofpain. Thatsaid,tomostpharmacologists,painisthemostobviousindicationfor aroleorsensorynervesindisease. Webelievethatthelessonslearntfromthestudy ofneuropathicpainwillbeinvaluableforresearchersintheothertherapeuticareas covered inthisvolume. Sincemostinterest hasfocusedontheroleofsensory nervesinneuropathicpain,wehaveaddedanumberofchaptersdevotedtothis subject. Thebookisorganizedinthreeparts,coveringthetypesandrolesofsensory nervesinsomaticandvisceraldisorders(PartI),speci?ctargetsonsensorynerves relevanttopainandvisceraldisorders(PartII)andadescriptionofcurrentand futuretherapeuticstrategiesfortargetingsensorynerves(PartIII). The?rsttwochaptersinPartIaredevotedtodescribingtheclinicalfeaturesof neuropathicpainandvisceralpain. Ourintentionisfortheauthorstoprovidea clinicalviewpointonthefeaturesoftheseconditionsandtheadvantages/disadv- tagesofcurrenttreatmentmodalities. Thenext?vechaptersinPartIfocusonthe roleofsensorynervesinotherpathologicalconditions. Severalcommonthemes willemergeinthispart,includingthemodeofsensorynerveactivationinvarious tissues and organs, the alterations in sensory nerve excitability associated with disease,andtheimportanceofin?ammationandin?ammatorymediatorsininiti- ingalteredsensorynervefunctionindisease. v vi Preface Whilstthe?rstpartfocusesontheclinicaland/orsystemsphysiology,PartIIhas itsfocusatthecellandmolecularlevel. Thisparthighlightsthecurrentundersta- ingofproteins/ionchannels/mediatorsthathavecreatedthemostintenserecent interestintheareaofsensorynervebiology. Together,thesechapterswillgivethe reader important knowledge about how sensory nerve function can be altered pharmacologically. Thelastchapterinthispartdescribestheprocessesthatgive risetoalteredneuralre?exesatthecentrallevel. Themechanismsdescribedin thesechaptersreinforcetheroleofproteins/mediatorshighlightedinthepreceding chapters. Theroleofthesecellular,molecularandphysiologicalprocessesinthe diseasesdiscussedinPart1areemphasized. TheaimofPartIIIistohighlightpotentialdrugtargetsthatmightaltersensory nervefunction. Mostoftheworkhasbeendevotedtothetreatmentofneuropathic painandsothispartheavilyemphasizesthissubject. However,aswillbeapparent fromPartI,manyofthesetargetscouldbeutilizedinothertherapeuticareasthat implicatesensorynervesintheirpathophysiologicalprocesses. Thefocusofthe chaptersisonopioidsandmodulatorsofionchannelsandthenthe?nalchapteris devotedtofuturetreatmentstrategiesforneuropathicpain. Finally,wewouldliketothankallthecontributors,includingco-authors,who agreedtowritechaptersforthisbookandthepublishers,especiallySusanneDathe, fortheirpatienceandassistance. Baltimore B. J. Canning London D. Spina Contents PartI RoleofSensoryNervesinDisease NeuropathicPain:AClinicalPerspective ...3 RalfBaron VisceralPain:TheNeurophysiologicalMechanism...31 JyotiN. Sengupta Migraine ...75 SilviaBenemei,PaolaNicoletti,JayG. Capone,Francesco DeCesaris,andPierangeloGeppetti AfferentNerveRegulationofBladderFunctioninHealth andDisease ...91 WilliamC. deGroatandNaokiYoshimura SensoryNervesandAirwayIrritability...139 B. J. CanningandD. Spina RegulationofCardiacAfferentExcitabilityinIschemia...185 Liang-WuFuandJohnC. Longhurst RolesofGastro-oesophagealAfferentsintheMechanisms andSymptomsofRe?uxDisease ...227 AmandaJ. PageandL. AshleyBlackshaw PartII CellandMolecularMechanismsRegulatingSensory NerveFunction TransientReceptorPotentialChannelsonSensoryNerves ...261 S. R. EidandD. N. Cortright Acid-SensitiveIonChannelsandReceptors ...283 PeterHolzer PurinesandSensoryNerves...333 GeoffreyBurnstock vii viii Contents Sensory-Nerve-DerivedNeuropeptides: PossibleTherapeuticTargets ...393 ElizabethS. Fernandes,SabineM. SchmidhuberandSusanD. Brain CytokineandChemokineRegulationofSensory NeuronFunction ...417 RichardJ. Miller,HosungJung,SoniaK. BhangooandFletcherA. White TheRoleofPeptidesinCentralSensitization ...451 V. S. Seybold PartIII CurrentandFutureTreatmentStrategiesTargeting SensoryNerves OpioidsandSensoryNerves ...495 ChristophSteinandChristianZollner ThePharmacologyofVoltage-GatedSodiumChannels inSensoryNeurones ...519 ReginaldJ. DochertyandClareE. Farmer RoleofCalciuminRegulatingPrimarySensory NeuronalExcitability ...563 T. D. Gover,T. H. MoreiraandD. Weinreich FutureTreatmentStrategiesforNeuropathicPain...589 FabienMarchand,NicholasG. JonesandStephenB.

Primary care clinicians are called on to care for adolescents in a time with increasing pharmacologic agents that are available in the management of these patients. The emphasis in this book is on the current pharmacologic treatment of common medical disorders in adolescents. Selected topics of practical relevance in adolescent medicine are covered. The goal of this book is to provide a succinct and practical guide specifically written for practicing physicians and allied health professionals who work with adolescents.

This volume provides reviews of six topics demonstrating the breadth of the field and recent successes in medicinal chemistry. Each of the first five chapters takes an important biochemical target as its theme and provides an insight into current progress in drug design. The last chapter focuses on the vital subject of pharmacokinetics and the great strides that have been made in this discipline during the past decade. All chapters provide an insight into the skills required of the modern medicinal chemist, in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.
*Presents the latest research in the field of drug discovery
*Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect

The suspension dosage form has long been used for poorly soluble active ingre- ents for various therapeutic indications. Development of stable suspensions over the shelf life of the drug product continues to be a challenge on many fronts. A good understanding of the fundamentals of disperse systems is essential in the development of a suitable pharmaceutical suspension. The development of a s- pension dosage form follows a very complicated path. The selection of the proper excipients (surfactants, viscosity imparting agents etc.) is important. The particle size distribution in the finished drug product dosage form is a critical parameter that significantly impacts the bioavailability and pharmacokinetics of the product. Appropriate analytical methodologies and instruments (chromatographs, visco- ters, particle size analyzers, etc.) must be utilized to properly characterize the s- pension formulation. The development process continues with a successful scale-up of the manufacturing process. Regulatory agencies around the world require cli- cal trials to establish the safety and efficacy of the drug product. All of this devel- ment work should culminate into a regulatory filing in accordance with the regulatory guidelines. Pharmaceutical Suspensions, From Formulation Development to Manufacturing, in its organization, follows the development approach used widely in the pharmaceutical industry. The primary focus of this book is on the classical disperse system - poorly soluble active pharmaceutical ingredients s- pended in a suitable vehicle.